Doxorubicin induces the persistent activation of intracellular transglutaminase 2 that protects from cell death

Molecules and Cells

Volumn 33, Issue 3, 2012, Pages 235-241

  Cho, Sung Yup ^a   Jeong, Eui Man ^a   Lee, Jin Haeng ^a   Kim, Hyo Jun ^a   Lim, Jisun ^a   Kim, Chai Wan ^a   Shin, Dong Myung ^b   Jeon, Ju Hong ^a   Choi, Kyungho ^c   Kim, In Gyu ^a  

^a Seoul National University   (South Korea)

^b University of Ulsan   (South Korea)

^c National Cancer Center   (South Korea)

Author keywords

Activation; Doxorubicin; Intracellular activity; Transglutaminase 2

Indexed keywords

ACETYLCYSTEINE; CAFFEINE; DOUBLE STRANDED DNA; DOXORUBICIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA STRAND BREAKAGE; DOUBLE STRANDED DNA BREAK; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; MOUSE; NONHUMAN; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAFFEINE; CELL SURVIVAL; CELLS, CULTURED; CHELATING AGENTS; DOXORUBICIN; EGTAZIC ACID; ENZYME ACTIVATION; ENZYME ACTIVATORS; GENE EXPRESSION; GTP-BINDING PROTEINS; HUMANS; INTRACELLULAR FLUID; MICE; SIGNAL TRANSDUCTION; TRANSGLUTAMINASES;

EID: 84863451458     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.1007/s10059-012-2201-9     Document Type: Article

References (36)

1. Antonyak, M. A., McNeill, C. J., Wakshlag, J. J., Boehm, J. E., and Cerione, R. A. (2003). Activation of the Ras-ERK pathway inhibits retinoic acid-induced stimulation of tissue transglutaminase expression in NIH3T3 cells. J. Biol. Chem. 278, 15859-15866. (Pubitemid 36799701)
2. Antonyak, M. A., Miller, A. M., Jansen, J. M., Boehm, J. E., Balkman, C. E., Wakshlag, J. J., Page, R. L., and Cerione, R. A. (2004). Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J. Biol. Chem. 279, 41461-41467. (Pubitemid 39313586)
3. 2+-ATPase gene transcription. Circ. Res. 86, 8-14. (Pubitemid 30044162)
4. Boehm, J. E., Singh, U., Combs, C., Antonyak, M. A., and Cerione, R. A. (2002). Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J. Biol. Chem. 277, 20127-20130. (Pubitemid 34967301)
5. Dalton, T. P., Shertzer, H. G., and Puga, A. (1999). Regulation of gene expression by reactive oxygen. Annu. Rev. Pharmacol. Toxicol. 39, 67-101. (Pubitemid 29222552)
6. 2+-dependent transamidation activity in the protection afforded by tissue transglutaminase against doxorubicin-induced apoptosis. Biochemistry (Mosc) 45, 13163-13174. (Pubitemid 44707677)
7. Ermak, G., and Davies, K. J. (2002). Calcium and oxidative stress: from cell signaling to cell death. Mol. Immunol. 38, 713-721. (Pubitemid 34158874)
8. Fesus, L., and Szondy, Z. (2005). Transglutaminase 2 in the balance of cell death and survival. FEBS Lett. 579, 3297-3302. (Pubitemid 40804677)
9. Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57, 727-741. (Pubitemid 29094544)
10. Han, J. A., and Park, S. C. (1999). Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J. Cancer Res. Clin. Oncol. 125, 89-95. (Pubitemid 29161460)
11. Herman, J. F., Mangala, L. S., and Mehta, K. (2006). Implications of increased tissue transglutaminase (TG2) expression in drugresistant breast cancer (MCF-7) cells. Oncogene 25, 3049-3058. (Pubitemid 43780469)
12. Iismaa, S. E., Mearns, B. M., Lorand, L., and Graham, R. M. (2009). Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol. Rev. 89, 991-1023.
13. Jang, G. Y., Jeon, J. H., Cho, S. Y., Shin, D. M., Kim, C. W., Jeong, E. M., Bae, H. C., Kim, T. W., Lee, S. H., Choi, Y., et al. (2010). Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene 29, 356-367.
14. Jeon, J. H., Kim, C. W., Shin, D. M., Kim, K., Cho, S. Y., Kwon, J. C., Choi, K. H., Kang, H. S., and Kim, I. G. (2003). Differential incorporation of biotinylated polyamines by transglutaminase 2. FEBS Lett. 534, 180-184. (Pubitemid 36084539)
15. Jeong, E. M., Kim, C. W., Cho, S. Y., Jang, G. Y., Shin, D. M., Jeon, J. H., and Kim, I. G. (2009). Degradation of transglutaminase 2 by calcium-mediated ubiquitination responding to high oxidative stress. FEBS Lett. 583, 648-654.
16. Kim, D. S., Park, K. S., and Kim, S. Y. (2009). Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors. Front. Biosci. 14, 2514-2521.
17. Kurz, E. U., Douglas, P., and Lees-Miller, S. P. (2004). Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J. Biol. Chem. 279, 53272-53281. (Pubitemid 40051831)
18. Kweon, S. M., Lee, Z. W., Yi, S. J., Kim, Y. M., Han, J. A., Paik, S. G., and Ha, S. S. (2004). Protective role of tissue transglutaminase in the cell death induced by TNF-alpha in SH-SY5Y neuroblastoma cells. J. Biochem. Mol. Biol. 37, 185-191.
19. Lavin, M. F. (2008). Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat. Rev. Mol. Cell Biol. 9, 759-769.
20. Müller, I., Niethammer, D., and Bruchelt, G. (1998). Anthracyclinederived chemotherapeutics in apoptosis and free radical cytotoxicity. Int. J. Mol. Med. 1, 491-494.
21. Nozaki, N., Shishido, T., Takeishi, Y., and Kubota, I. (2004). Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 110, 2869-2874. (Pubitemid 39473611)
22. Oh, K., Park, H. B., Byoun, O. J., Shin, D. M., Jeong, E. M., Kim, Y. W., Kim, Y. S., Melino, G., Kim, I. G., and Lee, D. S. (2011). Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice. J. Exp. Med. 208, 1707-1719.
23. Park, K. S., Kim, D. S., Jeong, K. C., and Kim, S. Y. (2009). Increase in transglutaminase 2 expression is associated with NF-kappaB activation in breast cancer tissues. Front. Biosci. 14, 1945-1951.
24. Sabisz, M., and Skladanowski, A. (2008). Modulation of cellular response to anticancer treatment by caffeine: inhibition of cell cycle checkpoints, DNA repair and more. Curr. Pharm. Biotechnol. 9, 325-336.
25. Sarkaria, J. N., Busby, E. C., Tibbetts, R. S., Roos, P., Taya, Y., Karnitz, L. M., and Abraham, R. T. (1999). Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 59, 4375-4382. (Pubitemid 29418757)
26. Shin, D. M., Jeon, J. H., Kim, C. W., Cho, S. Y., Kwon, J. C., Lee, H. J., Choi, K. H., Park, S. C., and Kim, I. G. (2004). Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation: implications of transglutaminase 2 in age-related cataractogenesis. J. Biol. Chem. 279, 15032-15039.
27. Shin, D. M., Kang, J., Ha, J., Kang, H. S., Park, S. C., Kim, I. G., and Kim, S. J. (2008a). Cystamine prevents ischemia-reperfusion injury by inhibiting polyamination of RhoA. Biochem. Biophys. Res. Commun. 365, 509-514. (Pubitemid 350186281)
28. Shin, D. M., Jeon, J. H., Kim, C. W., Cho, S. Y., Lee, H. J., Jang, G. Y., Jeong, E. M., Lee, D. S., Kang, J. H., Melino, G., et al. (2008b). TGFβ mediates activation of transglutaminase 2 in response to oxidative stress that leads to protein aggregation. FASEB J. 22, 2498-2507. (Pubitemid 351948667)
29. Smith, L., Watson, M. B., O'Kane, S. L., Drew, P. J., Lind, M. J., and Cawkwell, L. (2006). The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol. Cancer. Ther. 5, 2115-2120. (Pubitemid 44336583)
30. Sohn, J., Kim, T. I., Yoon, Y. H., Kim, J. Y., and Kim, S. Y. (2003). Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. J. Clin. Invest. 111, 121-128. (Pubitemid 36134855)
31. 2+]i) is consistently required to induce the execution phase of apoptosis. Cell Death Differ. 9, 561-573. (Pubitemid 34521183)
32. Tsuruo, T., Naito, M., Tomida, A., Fujita, N., Mashima, T., Sakamoto, H., and Haga, N. (2003). Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 94, 15-21. (Pubitemid 36575852)
33. Wittlinger, M., Grabenbauer, G. G., Sprung, C. N., Sauer, R., and Distel, L. V. (2007). Time and dose-dependent activation of p53 serine 15 phosphorylation among cell lines with different radiation sensitivity. Int. J. Radiat. Biol. 83, 245-257. (Pubitemid 46399005)
34. Yamaguchi, H., and Wang, H. G. (2006). Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells. Mol. Cell. Biol. 26, 569-579. (Pubitemid 43089769)
35. 2+]-dependent generation of intracellular reactive oxygen species mediates maitotoxininduced cellular responses in human umbilical vein endothelial cells. Mol. Cells 21, 121-128.
36. Yuan, L., Choi, K., Khosla, C., Zheng, X., Higashikubo, R., Chicoine, M. R., and Rich, K. M. (2005). Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol. Cancer Ther. 4, 1293-1302.